Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
- DOI
- 10.1016/j.jtocrr.2020.100114
- Published
- 2021 Feb
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2020.100114,
title = {Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.},
author = {Yang JC and Reckamp KL and Kim YC and Novello S and Smit EF and Lee JS and Su WC and Akerley WL and Blakely CM and Groen HJM and Bazhenova L and Carcereny Costa E and Chiari R and Hsia TC and Golsorkhi T and Despain D and Shih D and Popat S and Wakelee H},
year = {2021},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2020.100114},
url = {https://doi.org/10.1016/j.jtocrr.2020.100114}
}RIS
TY - JOUR TI - Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. AU - Yang JC AU - Reckamp KL AU - Kim YC AU - Novello S AU - Smit EF AU - Lee JS AU - Su WC AU - Akerley WL AU - Blakely CM AU - Groen HJM AU - Bazhenova L AU - Carcereny Costa E AU - Chiari R AU - Hsia TC AU - Golsorkhi T AU - Despain D AU - Shih D AU - Popat S AU - Wakelee H PY - 2021 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2020.100114 UR - https://doi.org/10.1016/j.jtocrr.2020.100114 ER -
APA
JC, Y., KL, R., YC, K., S, N., EF, S., JS, L., WC, S., WL, A., CM, B., HJM, G., L, B., E, C. C., R, C., TC, H., T, G., D, D., D, S., S, P., & H, W. (2021). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2020.100114
Source records
- pubmed · retrieved 2026-09-26T01:41:05.143Z